Table 2.

Compliance with study treatment

A. Number (%) of eligible, randomized, no-cancer subjects on treatment
SeleniumPlacebo
At 6 mo194 (93.7)192 (94.1)
At 1 y181 (90.5)178 (90.8)
At 2 y165 (88.2)157 (87.2)
At 3 y120 (78.9)122 (81.3)
B. Plasma selenium concentrations by study arm in randomly selected subset samples
 Selenium (N = 46)Placebo (N = 51)
Median (p25–p75)a
At baseline138.1 (104.7–166.4)135.2 (113.3–166.8)
At 6 mo220.9 (181.9–257.9)b, c152.7 (119.7–169.4)
At 1 y240.4 (203.6–275.9)b, c145.7 (121.2–166.7)
At 2 y259.3 (207.2–305.1)b, c154.3 (125.8–177.9)
At 3 y261.2 (233.0–290.4)b, c152.1 (125.1–185.9)

Abbreviations: p25, 25th percentile; p75, 75th percentile.

  • aThe median and p25 and p75 concentrations represented in nanogram per milliliter. Twenty-five percent of the concentrations fall below the p25 level; 75% of the concentrations fall below the p75 level.

  • bP < 0.05, compared with baseline levels.

  • cP < 0.05, compared with change among placebo patients.